HHS program advances experimental Ebola vaccine regimen
The regimen is comprised of two components, a prime (Ad26.ZEBOV) and a boos (MVA-BN-Filo). In January, the U.S. and U.K. began the first clinical studies of this regimen. A phase 2 study began in July.
This progressive development is part of an international effort to create vaccines for a variety of illnesses that are similar to Ebola. The latest advancement is thanks to a four-year agreement worth $28.5 million.
“History has shown that Ebola doesn’t really disappear -- there have been roughly 35 outbreaks in the past 40 years -- so we need to be fully prepared for the future with licensed vaccines and therapies for this disease,” Robin Robinson, Ph.D., director of ASPR’s Biomedical Advanced Research and Development Authority (BARDA), the office that will manage the project, said. “By pursuing multiple Ebola vaccines and leveraging innovative technology, we can address biodefense needs here in the U.S., while spurring affordable options for global use.”